ArticleAmerican journal of cancer research2025
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.Frontiers in neurologyPooled it
- Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review.Endocrine journal · 2026Review
- Association between the metabolic score for insulin resistance trajectory and new-onset metabolic syndrome: a retrospective cohort study based on health check-up data in China.Lipids in health and disease · 2025Article
- Elevated thyroid-stimulating hormone correlates with insulin resistance and β-cell dysfunction in type 2 diabetes with subclinical hypothyroidism.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on glycemic control, islet cell function, and insulin resistance in type 2 diabetes mellitus (T2DM) patients with T1-stage renal cell carcinoma (RCC). A retrospective cohort of 175 patients was divided into a control group receiving SGLT2i monotherapy (n = 84) and an observation group receiving combination therapy with SGLT2i and GLP-1RA (n = 91). Propensity score matching (PSM) was employed to balance baseline characteristics, resulting in 35 patients per group. After treatment, the observation group showed significant improvements in fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), and glycated hemoglobin (HbA1c) compared to the control group (P < 0.001). Islet cell function markers, including fasting insulin and HOMA-IR, also improved significantly (P < 0.001). Renal function markers, such as serum creatinine, blood urea nitrogen, and urinary albumin excretion rate, were better in the observation group (P < 0.05). Multivariate analysis identified older age (OR = 7.434, P = 0.025), higher BMI (OR = 6.812, P = 0.003), and high-fat diet (OR = 0.044, P = 0.005) as independent risk factors for insulin resistance. The combined use of SGLT2i and GLP-1RA demonstrated superior efficacy in improving glycemic variability, insulin sensitivity, and renal function, highlighting its potential as an effective strategy for managing patients with T2DM and RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.